)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Aclaris Therapeutics
Aclaris Therapeutics (ACRS) investor relations material
Aclaris Therapeutics Leerink Global Healthcare Conference 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Leerink Global Healthcare Conference 2026 summary10 Mar, 2026
Company overview and recent progress
Focus on large and small molecule therapeutics in immunology and inflammation, with three clinical-stage assets and a fourth nearing IND submission later this year.
Large molecule pipeline includes TSLP mAb (ATI-045) in phase II for atopic dermatitis (AD) and a bispecific construct (ATI-052) targeting TSLP and IL-4R, both with data readouts expected by year-end.
Oral small molecule ATI-2138 is being positioned for a lead indication, supported by a full phase II-ready package and long-term toxicology data.
Next-generation ITK inhibitor, engineered to remove JAK activity, is advancing toward IND in the second half of the year.
TSLP antibody program (ATI-045)
Demonstrates 20x longer TSLP binding retention and superior potency compared to tezepelumab and other clinical candidates.
Phase II-A open-label study showed 94% EASI response and 88% IGA 0/1, prompting advancement to a 96-subject, double-blind, placebo-controlled phase II trial with data expected by year-end.
Dosing interval could extend to every 3 months due to a 23-day half-life and durable efficacy observed post-dosing.
Stringent patient screening and image review processes are used to minimize placebo response and ensure accurate diagnosis.
Success bar is set at achieving statistical significance and responder rates comparable to or exceeding Dupixent, with safety as a key differentiator.
Bispecific antibody program (ATI-052)
Early phase I data show 100% target inhibition and a 26-day half-life, with potential for 2-3 month dosing intervals.
Ongoing phase I-B studies in asthma and AD will inform phase II design, with expectations of a 10% improvement in responder rates over current standards.
Immunogenicity data so far show no enhanced clearance or neutralization, with further analysis pending.
Asthma is prioritized for phase II-B, leveraging mechanistic differentiation between TSLP and IL-4R for broad patient applicability.
Optimal dosing interval for ATI-045 market adoption?
Factors driving ATI-2138 lead indication choice
How does Pfizer data de-risk your bispecific strategy
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Next Aclaris Therapeutics earnings date
Q1 20267 May, 2026
Aclaris Therapeutics
Next Aclaris Therapeutics earnings date
Q1 20267 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Aclaris Therapeutics Inc. is a clinical-stage biopharmaceutical company primarily engaged in the development of novel drug candidates for immuno-inflammatory diseases. Leveraging its core expertise in drug discovery, development, and kinase inhibition, Aclaris focuses on creating small molecule therapies for people affected by underserved immuno-inflammatory conditions. Its proprietary KINect® technology platform enables the development of clinical candidates targeting challenging kinases with novel approaches. Additionally, Aclaris operates Confluence Discovery Technologies, Inc., a full-service drug discovery and early development contract research organization. This subsidiary offers research partnership services across therapeutic areas and gene families, with expertise in a range of scientific disciplines including cell and molecular biology, biochemistry, enzymology, and immunology. he company is headquartered in Wayne, Pennsylvania, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage